

# Synthesis and *in vitro* antimalarial activity of novel chalcone derivatives

FJ Smit

BSc (UP), Hons BSc (NWU), MSc (NWU)

20926588

Thesis submitted in fulfilment of the requirements for the degree

**Philosophiae Doctor**

in Pharmaceutical Chemistry


North-West University (Potchefstroom Campus)



Supervisor: Prof DD N'Da

May 2014

It all starts here™



# Solemn Declaration

---



NORTH-WEST UNIVERSITY  
YUNIBESITHI YA BOKONE-BOPHIRIMA  
NOORDWES-UNIVERSITEIT  
POTCHEFSTROOM CAMPUS

I, **FRANS JOHANNES SMIT**,

herewith declare that the thesis entitled,

**SYNTHESIS AND *IN VITRO* ANTIMALARIAL ACTIVITY OF NOVEL CHALCONE DERIVATIVES**

which I herewith submit to the North-West University, Potchefstroom Campus, in compliance with the requirements set for the degree, **Philosophiae Doctor**, is my own work, has been language edited and has not already been submitted to any other university.

I understand and accept that the copies that are submitted are the property of the University.

Signature of student: \_\_\_\_\_

University number: **20926588**

Signed at **Potchefstroom** this \_\_\_\_\_ day of \_\_\_\_\_ 2013

Declared before me on this \_\_\_\_\_ day of \_\_\_\_\_ 2013

Commissioner of Oaths: \_\_\_\_\_

## **Declaration by Supervisor / Promoter / Research Director**

The undersigned declares:

1. that the student attended an approved module(s) of study for the relevant qualification and that the work for the course has been completed, or that work approved by the Senate has been done;
2. that the student has complied with the minimum duration of study as stated in the calendar;
3. the student is hereby granted permission to submit his/her mini-dissertation/dissertation or thesis;
4. that registration/amendment of the title has been approved;
5. that the appointment/amendment of examiners has been finalised;
6. that the student's work has been submitted to TurnItIn and a satisfactory report has been obtained; and
7. that all the procedures have been followed according to the Manual for Postgraduate Studies.

Signature Supervisor/Promoter: \_\_\_\_\_ Date: \_\_\_\_\_

Signature Research Director: \_\_\_\_\_ Date: \_\_\_\_\_

# Preface

---

This thesis is submitted in an article format in accordance with the General Academic Rules (A.13.7.3) of the North-West University. Three articles, two of which have been submitted, are included in this thesis:

## **Chapter 3: Article 1**

Synthesis, *in vitro* antimalarial activity and cytotoxicity of novel chalcone-quinoline amides

## **Chapter 4: Article 2**

Synthesis, antimalarial and cytotoxic activity of novel aminoferrocenyl-chalcone amides

## **Chapter 5: Article 3**

Synthesis and biological evaluation of dihydroartemisinin-chalcone esters

The respective Journals of the submitted articles grant the author the right to include these articles in a thesis. Permission for the Journals is given within their Author's Guides:

Permission from Elsevier: <http://www.journals.elsevier.com/bioorganic-and-medicinal-chemistry/>

Permission from ScienceDirect: <http://www.sciencedirect.com/science/journal/00404020>

Permission from ACS publication: <http://pubs.acs.org/page/jmcmr/submission/authors.html>

# Acknowledgments

---

I hereby wish to express my appreciation to the following individuals whose guidance enabled me to complete this project successfully:

- Prof DD N'Da, my Supervisor, for his insight, encouragement and support throughout the entire study.
- Dr JHL Jordaan, for his consistent support and for the collection of MS data.
- Prof JP Petzer, Director of the Department of Pharmaceutical Chemistry, for his support and input into the project.
- Prof J du Plessis, Director of PHARMACEN, for her support, encouragement, input and financial support throughout my study.
- Prof S van Dyk, Director of the School for Pharmacy, for her support.
- Dr A Lourens, for her invaluable input in this study.
- Mr A Joubert, for the collection of NMR data.
- The CSIR, for the biological screening of the first and second series.
- Prof L Birkholtz from UP, for her help and guidance, as well as biological screening of series 3.
- Dr HJR Lemmer and Mr N Barnard, for their help with collecting and elucidating DSC/TGA data.
- Dr JR Kriek and Dr V Lates, for their help with electrochemical determination.
- The NRF and the North-West University, for financial support.
- All the students at the Department, for their assistance and countless hours of devotion throughout the entire study.
- My friends and family, for their support and love.

I give thanks to my Heavenly Father, without whom I could achieve nothing.

# Abstract

---

Malaria is endemic in 106 countries worldwide. This disease is caused by a parasite from the genus *Plasmodium*. Of the five species that infect humans, *Plasmodium falciparum* is the most virulent, with over three billion people at risk and around 660 000 deaths reported in 2011. Of these deaths, 91% were in the African region, while 86% were children under the age of five. In light of the widespread development of resistance by malaria parasites against the classic antimalarial drugs, such as chloroquine (CQ) and now the established tolerance towards the widely used artemisinins, an immense need exists for identifying and developing new and effective antiplasmodial drugs. In search for such new antimalarial drugs, three chalcone based series of compounds were prepared and investigated during this study.

The first series (Chapter 3) comprised 4-aminoquinoliny-chalcone amides, which were synthesized through amidation of carboxylic acid-functionalised chalcone with aminoquinolines, using 1,1'-carbonyldiimidazole (CDI) as coupling agent. These compounds were screened alongside CQ against the CQ sensitive (3D7) and CQ resistant (W2) strains of *P. falciparum*. Cytotoxicity was assessed against the WI-38 cell line. The amide, featuring the 1,6-diaminohexane linker, was found the most active of all these new novel compounds tested. It was found to be as potent as CQ against 3D7, while displaying a two-fold higher activity than CQ against the W2 strain, coupled with good selective antimalarial activity (SI = 435) towards the parasitic cells.

The second series (Chapter 4) consisted of aminoferrocenyl-chalcone amides, synthesized through condensation of a chalcone with an aminoferrocenyl. These compounds were screened against the 3D7, and antifolate- and CQ resistant (FCR3) strains of *P. falciparum* and cytotoxicity was determined against the WI-38 line. The most active compound of this series was the amide, containing the 1,2-diaminoethane linker, which showed 130- and 42 times less potency than CQ against the 3D7 and W2 strains, respectively.

The third series of antimalarials (Chapter 5) involved dihydroartemisinyl-chalcone esters, synthesized through esterification of chalcones with DHA. These compounds were screened against 3D7 and W2 strains of *P. falciparum*, while the cytotoxicity was determined against the WI-38 line. Those esters featuring oxygenated aryl rings were three- to four-fold more potent than current clinically used artesunate against both *P. falciparum* strains. They were also screened *in vitro* against a panel of three cancer cell lines consisting of TK-10, UACC-

62 and MCF-7. Thermogravimetric analysis revealed that the targeted hybrids were all thermally more stable than DHA as a result of the presence of the chalcone moiety in their structures. This could prove beneficial to the high temperature storage conditions that prevail in most malaria endemic countries.

This study resulted in a number of compounds with varying antiplasmodial activity ranges. The compounds in series 3 were overall the most active, due to the incorporation of the highly active dihydroartemisinin pharmacophore. The chalcone moiety, especially, demonstrated a large scope for future development, owing to the ease of synthesis and the relatively low costs involved. The most active compounds of the three series could serve as potential lead compounds in the future development of more effective antimalarial drugs.

*Keywords: Plasmodium falciparum, malaria, chalcone, amino quinoline, aminoferrocenyl, dihydroartemisinin*

# Opsomming

---

Malaria is endemies aan 106 lande regoor die wêreld. Hierdie siekte word deur 'n parasiet uit die genus *Plasmodium* veroorsaak. Uit die vyf spesies wat mense kan besmet, is *Plasmodium falciparum* die mees virulente, met meer as drie miljard lewens wat in gevaar is, terwyl ongeveer 660 000 sterftes in 2011 voorgekom het. Uit hierdie gerapporteerde sterftes het 91% in die Afrika-streek voorgekom, waarvan 86% kinders jonger as vyf jaar was. In die lig van die wydverspreide weerstand van die malariaparasiete teen die klassieke antimalariamiddels, soos chlorokien (CQ), en nou die gevestigde toleransie teen die algemeen-gebruikte artemisiniene, bestaan daar 'n geweldige behoefte om nuwe, doeltreffende anti-malariamiddels te identifiseer en te ontwikkel. In 'n soektog na nuwe antimalariamiddels is drie chalkoon-gebaseerde reekse verbindings tydens hierdie studie voorberei en ondersoek.

Die eerste reeks middels (Hoofstuk 3) het 4-aminokinolinol-chalkoon-amiede behels, wat deur die amidasie van karboksielsuur-gefunksionaliseerde chalkoon met aminokinoliene, deur middel van 1,1'-karboniëldiimidiasool as koppelmiddel, gesintetiseer is. Hierdie verbindings is saam met CQ teen die CQ-sensitiewe (3D7) en CQ-weerstandige (W2) stamme van *P. falciparum* getoets. Sitotoksiteit is teen die WI-38-sellyn geëvalueer. Die amied met die 1,6-diaminoheksaan-skakel was die aktiefste van almal. Daar is bevind dat dit so effektief soos CQ teen 3D7 was, terwyl dit twee keer hoër aktiwiteit teen die W2-stam getoon het, tesame met goeie selektiewe antimalaria-aktiwiteit (SI = 435) teen die parasitiese selle.

Die tweede reeks (Hoofstuk 4) het uit aminoferroseniol-chalkoon-amiede bestaan, wat deur kondensasie van 'n chalkoon met 'n aminoferroseniol gesintetiseer was. Hierdie verbindings is teen die 3D7-, en antifolaat- en CQ-weerstandige (FCR3) stamme van *P. falciparum* getoets en sitotoksiteit is teen die WI-38-lyn bepaal. Die aktiefste verbinding uit hierdie reeks is die amied met die 1,2-diaminoëtaan-skakel, wat 130- en 42 keer minder aktief as CQ teen die 3D7- en W2-stamme, onderskeidelik, was.

Die derde reeks antimalariamiddels (Hoofstuk 5) het dihidroartemisiniol-chalkoon-esters behels, wat deur die verestering van chalkone met DHA gesintetiseer was. Hierdie verbindings is teen die 3D7- en W2-stamme van *Plasmodium falciparum* getoets, terwyl die sitotoksiteit teen die WI-38-sellyn geëvalueer is. Daardie esters met geoksigeneerde

arielringe is drie tot vier keer meer aktief as die artesunaat wat tans klinies teen albei *P. falciparum*-stamme gebruik word. Hierdie verbindings is ook teen drie kanker sel-lyne, opgemaak uit TK-10, UACC-62 and MCF-7 kanker selle, geëvalueer. Termogravimetriese ontleding het getoon dat al die geteikende hibriede, as gevolg van die aanwesigheid van die chalkoon-gedeelte in hulle strukture, termies meer stabiel as DHA was. Dit mag tot voordeel van die hoë temperatuurstoorkondisies, soos wat in die meeste malaria-endemiese lande heers, bevind word.

Hierdie studie het tot 'n aantal verbindings met wisselende aktiwiteitsvlakke aanleiding gegee. Die verbindings in reeks 3 was oorkoepelend die aktiefste, weens die inkorporasie van die uiters aktiewe dihidroartemesinien-farmakofoor. Die chalkoon-komponent, veral, het geweldige potensiaal vir toekomstige ontwikkeling getoon, as gevolg van die gemak waarmee dit gesintetiseer word en die relatief lae koste betrokke. Die aktiefste verbindings uit al die drie reekse kan as potensiese leidraadverbindings vir die ontwikkeling van doeltreffender antimalariamiddels in die toekoms dien.

*Sleutelwoorde: Plasmodium falciparum, malaria, chalkoon, aminokinolien, aminoferroseniel, dihidroartemesinien*

# List of Contents

---

Solemn Declaration.....	i
Preface.....	ii
Acknowledgments.....	iii
Abstract.....	iv
Opsomming.....	vi
List of Contents.....	viii
List of Figures.....	xv
List of Tables and Schemes.....	xvii
List of Abbreviations.....	xviii
Chapter 1: Introduction and Problem Statement.....	1
1.1.    Background.....	1
1.2.    Aim.....	6
1.3.    Objectives.....	6
Chapter 2: Literature review.....	7
2.1.    Introduction.....	7
2.2.    Life cycle and pathogenesis.....	8
2.3.    Haemoglobin degradation.....	10
2.4.    Signs and symptoms.....	11
2.5.    Diagnosis.....	13
2.6.    Control and prevention.....	14
2.7.    Chemotherapy.....	16
2.7.1    Antifolates and hydroxynaphthoquinones.....	16
2.7.2    Antimicrobials.....	20
2.7.3    8-Aminoquinolines.....	21
2.7.4    Aryl-amino alcohols.....	22
2.7.5    4-Aminoquinolines.....	24

2.7.6	Artemisinin and derivatives.....	26
2.7.7	Chalcone compounds.....	29
2.7.8	Hybrid drug theory.....	31
2.7.9	Chalcone based hybrids.....	32
Chapter 3: Synthesis, in vitro antimalarial activity and cytotoxicity of novel chalcone-quinoline amides - Article 1.....		
		37
Abstract.....		40
1.	Introduction.....	40
2.	Materials and methods.....	41
2.1	Materials.....	41
2.2	General procedures.....	41
2.3	Biological evaluation.....	42
2.3.1	In vitro antimalarial assay.....	42
2.3.2	In vitro cytotoxicity.....	42
2.4	Synthesis.....	42
2.4.1	4-Amino-7-chloroquinolines, 1–9.....	42
2.4.1.1.	N-(2-Aminoethyl)-7-chloroquinolin-4-amine, 1.....	42
2.4.1.2.	N-(3-Aminopropyl)-7-chloroquinolin-4-amine, 2.....	42
2.4.1.3.	N-(4-Aminobutyl)-7-chloroquinolin-4-amine, 3.....	42
2.4.1.4.	N-(2-Aminopropyl)-7-chloroquinolin-4-amine, 4.....	43
2.4.1.5.	N-(6-Aminohexyl)-7-chloroquinolin-4-amine, 5.....	43
2.4.1.6.	{3-[(7-Chloroquinolin-4-yl)amino]propyl}(methyl)amine, 6.....	43
2.4.1.7.	N-{2-[2-(2-Aminoethoxy)ethoxy]ethyl}-7-chloroquinolin-4-amine, 7.....	44
2.4.1.8.	(3-Aminopropyl){3-[(7-chloroquinolin-4-yl)amino]propyl}methylamine, 8.....	44
2.4.1.9.	7-Chloro-4-(piperazin-1-yl)quinoline, 9.....	44
2.4.2.	4-[(1E)-3-(5-Methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzoic acid, 10.....	44
2.4.3.	4-Aminoquinolinyl-chalcone amides, 11-19.....	44
2.4.3.1	N-{2-[(7-Chloroquinolin-4-yl)amino]ethyl}-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 11.....	44
2.4.3.2.	N-{3-[(7-Chloroquinolin-4-yl)amino]propyl}-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 12.....	44
2.4.3.3.	N-{4-[(7-Chloroquinolin-4-yl)amino]butyl}-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 13.....	45
2.4.3.4.	N-{1-[(7-Chloroquinolin-4-yl)amino]propan-2-yl}-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 14.....	45

2.4.3.5.	N-{6-[(7-Chloroquinolin-4-yl)amino]hexyl}-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 15.....	45
2.4.3.6.	N-{3-[(7-Chloroquinolin-4-yl)amino]propyl}-N-methyl- 4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 16.....	45
2.4.3.7.	N-[2-(2-{2-[(7-Chloroquinolin-4-yl)amino]ethoxy}ethoxy)ethyl]-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 17.....	45
2.4.3.8.	N-[3-({3-[(7-Chloroquinolin-4-yl)amino]propyl} (methyl)amino)propyl]-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxo- prop-1-en-1-yl]benzamide, 18.....	45
2.4.3.9.	(2E)-3-(4-{[4-(7-Chloroquinolin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one, 19.....	46
2.4.4.	Chalconyl amides, 20–22.....	46
2.4.4.1.	4-[(1E)-3-(5-Methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamide, 20.....	46
2.4.4.2.	N-Butyl-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]-benzamide, 21.....	46
2.4.4.3.	(2E)-1-(5-Methylfuran-2-yl)-3-{4-[(morpholin-4-yl)carbonyl]-phenyl}prop-2-en-1-one, 22.....	46
3.	Results.....	46
3.1.	Chemistry.....	46
3.2.	Physicochemical properties.....	47
3.3.	In vitro antimalarial activity and cytotoxicity.....	47
4.	Discussion.....	48
4.1.	Chemistry.....	48
4.2.	Physicochemical properties.....	48
4.3.	In vitro antimalarial activity and cytotoxicity.....	49
5.	Conclusion.....	49
6.	Disclaimer.....	50
	References and notes.....	50
Chapter 4: Synthesis, antimalarial activity and cytotoxicity of novel aminoferrocenyl-chalcone amides - Article 2.....		
		51
	Abstract .....	53
1.	Introduction.....	54
2.	Materials and Methods .....	56
2.1	Materials.....	56
2.2	General procedures.....	56
2.3	Biological testing.....	57
2.3.1	<i>In vitro</i> antimalarial assay .....	57

2.3.2	<i>In vitro</i> cytotoxicity assay .....	58
2.4	Synthesis.....	58
2.4.1	Condensation of diamines with ferrocene carboxaldehyde .....	58
2.4.1.1.	N-ferrocenyl-1,2-diaminoethane, 1.....	59
2.4.1.2.	N-ferrocenyl-1,3-diaminopropane, 2 .....	59
2.4.1.3.	N-ferrocenyl-1,4-diaminobutane, 3.....	60
2.4.1.4.	N-ferrocenyl-2-aminoethylpiperazine, 4 .....	60
2.4.1.5.	N-ferrocenyl-1,2-diaminopropane, 5 .....	60
2.4.1.6.	N-ferrocenyl-N'-methyl-1,3-diaminopropane, 6 .....	60
2.4.1.7.	N-ferrocenyl-2,2'-(ethylenedioxy)bis(ethylamine), 7 .....	61
2.4.1.8.	N-ferrocenyl-N-(3-aminopropyl)-N-methylpropane-1,3-diamine, 8.....	61
2.4.1.9.	N-ferrocenyl-piperazine, 9 .....	61
2.4.2	4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzoic acid .....	62
2.4.3	Condensation of chalcone with aminoferrocenyl .....	64
2.4.3.1	N-[2-(ferrocenylamino)ethyl]-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamido oxalate, 11 .....	64
2.4.3.2	N-[3-(ferrocenylamino)propyl]-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamido oxalate, 12 .....	64
2.4.3.3	N-[4-(ferrocenylamino)butyl]-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamido oxalate, 13 .....	65
2.4.3.4	(2E)-3-[4-({4-[2-(ferrocenylamino)ethyl]piperazin-1-yl}carbonyl)phenyl]-1-(5-methylfuran-2-yl)prop-2-en-1-one oxalate, 14 .....	65
2.4.3.5	N-[1-(ferrocenylamino)propan-2-yl]-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamido oxalate, 15.....	66
2.4.3.6	N-[3-(ferrocenylamino)propyl]-N-methyl-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamido oxalate, 16.....	66
2.4.3.7	N-(2-{2-[2-(ferrocenylamino)ethoxy]ethoxy}ethyl)-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamido oxalate, 17.....	66
2.4.3.8	N-(3-{{3-(ferrocenylamino)propyl}(methyl)amino}propyl)-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzamido oxalate, 18 .....	67

2.4.3.9	(2E)-3-{4-[(4-ferrocenylpiperazin-1-yl)carbonyl]phenyl}-1-(5-methylfuran-2-yl)prop-2-en-1-one oxalate, 19.....	67
3.	Results .....	68
3.1	Chemistry .....	68
3.2	Reduction potential and physicochemical properties .....	68
3.3	<i>In vitro</i> antimalarial activity and cytotoxicity.....	69
4.	Discussion.....	71
4.1	Chemistry .....	71
4.2	Reduction potential and physicochemical properties .....	72
4.3	<i>In vitro</i> antimalarial activity and cytotoxicity.....	73
5.	Conclusion.....	75
	References.....	77
Chapter 5: Synthesis and biological evaluation of dihydroartemisinin-chalcone esters - Article		
	3.....	79
	Abstract .....	81
1.	Introduction.....	82
2.	Results .....	84
2.1	Chemistry .....	84
2.2	Physicochemical properties.....	84
2.3	<i>In vitro</i> antimalarial activity and cytotoxicity.....	86
2.4	<i>In vitro</i> antitumor activity .....	89
3.	Discussion.....	91
3.1	Chemistry .....	91
3.2	Physicochemical properties .....	93
3.3	<i>In vitro</i> antimalarial and cytotoxicity .....	95
3.4	<i>In vitro</i> antitumor activity .....	96
3.5	Selective antiplasmodial activity of hybrids .....	97
4.	Conclusion.....	97
5.	Materials and Methods .....	98
5.1	Materials.....	98

5.2	General procedures.....	98
5.3	Physicochemical properties .....	99
5.4	Biological evaluation.....	100
5.4.1	In vitro antimalarial assay .....	100
5.4.2	In vitro cytotoxicity assay .....	100
5.4.3	In vitro anticancer assay .....	101
5.5	Synthesis.....	102
5.5.1	Claisen-Schmidt condensation, 1 - 6 .....	102
5.5.1.1.	4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzoic acid, 1.....	102
5.5.1.2.	4-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]benzoic acid, 2.....	102
5.5.1.3.	4-[(1E)-3-(3-methoxy-4-nitrophenyl)-3-oxoprop-1-en-1-yl]benzoic acid, 3.....	103
5.5.1.4.	4-[(1E)-3-(3,4-dimethoxyphenyl)-3-oxoprop-1-en-1-yl]benzoic acid, 4 .....	103
5.5.1.5.	4-[(1E)-3-(2,4-dimethoxyphenyl)-3-oxoprop-1-en-1-yl]benzoic acid, 5 .....	103
5.5.1.6.	4-[(1E)-3-oxo-3-(2,3,4-trichlorophenyl)prop-1-en-1-yl]benzoic acid, 6 .....	104
5.5.2	Esterification of chalcone with dihydroartemisinin .....	104
5.5.2.1.	10 $\alpha$ -dihydroartemisiny-4-[(1E)-3-(5-methylfuran-2-yl)-3-oxoprop-1-en-1-yl]benzoate, 7 .....	106
5.5.2.2.	10-dihydroartemisiny-4-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]benzoate, 8 .....	106
5.5.2.3.	10-dihydroartemisiny-4-[(1E)-3-(3-methoxy-4-nitrophenyl)-3-oxoprop-1-en-1-yl]benzoate, 9 .....	107
5.5.2.4.	10-dihydroartemisiny-4-[(1E)-3-(3,4-dimethoxyphenyl)-3-oxoprop-1-en-1-yl]benzoate, 10 .....	107
5.5.2.5.	10-dihydroartemisiny-4-[(1E)-3-(2,4-dimethoxyphenyl)-3-oxoprop-1-en-1-yl]benzoate, 11 .....	108
5.5.2.6.	10 $\beta$ -dihydroartemisiny-4-[(1E)-3-oxo-3-(2,3,4-trichlorophenyl)prop-1-en-1-yl]benzoate, 12 .....	108
	References.....	110
	Chapter 6: Summary and Conclusion.....	112
	References.....	117
	Addendum A: Analytical data for Chapter 3.....	127

Addendum B: Analytical data for Chapter 4.....	187
Addendum C: Analytical data for Chapter 3 .....	228

# List of Figures

---

<b>Figure 1.1:</b> Global prevalence of malaria in 2010.....	1
<b>Figure 1.2:</b> Artemisinin and its derivatives. ....	2
<b>Figure 1.3:</b> Cysteine protease inhibitor E64 ( <b>A</b> ), general structure of a chalcone ( <b>B</b> ) and Licochalcone A ( <b>C</b> ). ....	3
<b>Figure 1.4:</b> Clinically used chloroquine (CQ).....	4
<b>Figure 1.5:</b> General structure of quinolinyl-chalcones .....	5
<b>Figure 2.1:</b> The complex life cycle of the Plasmodium sp. ....	9
<b>Figure 2.2:</b> Animation showing how the Plasmodium parasite acquire haemoglobin.....	10
<b>Figure 2.3:</b> Haemoglobin degradation in the digestive vacuole .....	11
<b>Figure 2.4:</b> Common symptoms and organs affected by malaria. ....	12
<b>Figure 2.5:</b> Biosynthetic pathway of Tetrahydrofolate. ....	17
<b>Figure 2.6:</b> Sub -class I antifolates: sulfadoxine ( <b>1</b> ) and dapsona ( <b>2</b> ).....	18
<b>Figure 2.7:</b> Sub-class II antifolates: pyrimethamine ( <b>3</b> ), proguanil ( <b>4</b> ) and its active metabolite cycloguanil ( <b>5</b> ). ....	18
<b>Figure 2.8:</b> Chemical structure of the hydroxynaphthoquinone atovaquone ( <b>6</b> ).....	19
<b>Figure 2.9:</b> Chemical structures of the antibiotics doxycycline ( <b>7</b> ) and clindamycin ( <b>8</b> ). ....	20
<b>Figure 2.10:</b> Chemical structure of primaquine ( <b>9</b> ).....	21
<b>Figure 2.11:</b> Chemical structures of quinine ( <b>10</b> ), quinidine ( <b>11</b> ), mefloquine ( <b>12</b> ) and halofantrine ( <b>13</b> ). ....	22
<b>Figure 2.12:</b> Chemical structures of 4-aminoquinolines: chloroquine (CQ, <b>14</b> ), amodiaquine ( <b>15</b> ) and piperazine ( <b>16</b> ). ....	25
<b>Figure 2.13:</b> Illustration of the PfCRT protein that allows the outward movement of CQ .....	26
<b>Figure 2.14:</b> Clinically used artemisinin ( <b>17</b> ), dihydroartemisinin ( <b>18</b> ), artemether ( <b>19</b> ), arteether ( <b>20</b> ) and artesunate ( <b>21</b> ). ....	27
<b>Figure 2.15:</b> Cysteine protease inhibitor E64 ( <b>22</b> ), general structure of a chalcone ( <b>23</b> ) and Licochalcone A ( <b>24</b> ). ....	30

<b>Figure 2.16:</b> Chemical structure of 1 <i>E</i> -(2,5-dichlorophenyl)-3(4-quinolinyl)-2-propen-1-one ( <b>25</b> ).....	30
<b>Figure 2.17:</b> Three binding possibilities of hybrid compounds. ....	32
<b>Figure 2.18:</b> General structure of quinolinyl-chalcone based hybrids ( <b>26</b> ) synthesized by Sharma <i>et al.</i> (2009).....	33
<b>Figure 2.19:</b> General structure of the keto-enamine chalcone-chloroquine based hybrid ( <b>27</b> ) .....	34
<b>Figure 2.20:</b> Chemical structure of ferroquine ( <b>28</b> ). ....	35
<b>Figure 2.21:</b> General structures of ferrocenyl-chalcones. ....	35
<b>Figure 2.22:</b> General structure of endoperoxide-chalcone based hybrids ( <b>31</b> ).....	36
<b>Figure 2.23:</b> General structure of dihydroartemisinin-chalcone based hybrids.....	36
 <b>Chapter 3:</b>	
<b>Figure 1:</b> General structure of a chalcone, cysteine protease inhibitor E64 and licochalcone A.....	41
<b>Figure 2:</b> General structures of quinolinyl-chalcones synthesized by Sharma <i>et al.</i> (A) and Sashidhara <i>et al.</i> (B).....	41
 <b>Chapter 4:</b>	
<b>Figure 1:</b> Chemical structures of ferroquine ( <b>FQ</b> ), chloroquine ( <b>CQ</b> ) and Licochalcone A.....	55
<b>Figure 2:</b> General structure of targeted compounds <b>11 – 18</b> , indicating the same chemical environment.....	73
 <b>Chapter 5:</b>	
<b>Figure 1:</b> Clinically used artemisinin and its derivatives. ....	82
<b>Figure 2:</b> General structure of a chalcone and Licochalcone A. ....	83
<b>Figure 3:</b> The percentage proliferation of chalcones <b>1, 4</b> and <b>5</b> , together with DHA and the molar combinations thereof.....	88

# List of Tables and Schemes

---

## Article 1:

<b>Scheme 1:</b>	Multi-step synthesis of 4-aminoquinolinyl-chalcone amides 11–19.....	43
<b>Scheme 2:</b>	Synthesis of chalconyl amides 20 – 22.....	46
<b>Table 1:</b>	Calculated physicochemical properties of compounds 10 - 22 and CQ.....	47
<b>Table 2:</b>	Antimalarial activity and cytotoxicity of screened amide compounds .....	47

## Article 2:

<b>Scheme 1:</b>	Multi-step synthesis of aminoferrocenyl-chalcone amides 11 – 19.....	63
<b>Table 1:</b>	Electrochemical potential of synthesized compounds .....	68
<b>Table 2:</b>	Calculated ADMET properties of synthesized compounds.....	69
<b>Table 3:</b>	<i>In vitro</i> antimalarial activity and cytotoxicity of screened compounds.....	70

## Article 3:

<b>Figure 1:</b>	Clinically used artemisinin and its derivatives. ....	82
<b>Figure 2:</b>	General structure of a chalcone and licochalcone A. ....	83
<b>Table 1:</b>	Calculated physicochemical properties of compounds 1 - 12, CQ, DHA and AS85	
<b>Table 2:</b>	Antimalarial activity and cytotoxicity of screened compounds .....	87
<b>Figure 3:</b>	The percentage cell proliferation with the addition of chalcones 1, 4 and 5, DHA and the molar combinations thereof, respectively. ....	88
<b>Table 3:</b>	Antitumor activity of screened compounds.....	90
<b>Table 4:</b>	Selective antiplasmodial activity versus anticancer activity of synthesized compounds.....	91
<b>Scheme 1:</b>	Multi-step synthesis of artemisinyl-chalcone esters 7 – 12.....	105

# List of Abbreviations

---

ACT	Artemisinin based combined therapy
ARF	Acute renal failure
AS	Artesunate
<sup>13</sup> C NMR	Carbon NMR
CBV	Cerebral blood volume
CM	Cerebral malaria
COSY	Correlation spectroscopy
CQ	Chloroquine
CQR	Chloroquine resistant
CQS	Chloroquine sensitive
Cyt bc1	Cytochrome bc1
DDT	Dichlorodiphenyltrichloroethane
DEPT	Distortionless enhancement by polarization transfer
DHA	Dihydroartemisinin
DHF	Dihydrofolate
DHFR	Dihydrofolate reductase
dhfr-ts	Dihydrofolate reductase-thymidylate synthase
DHPS	Dihydropteroate synthase
DNA	Deoxyribonucleic acid
DSC	Differential scanning calorimetry
FDA	Food and Drug Administration
G6PD	Glucose-6-phosphate dehydrogenase
<sup>1</sup> H NMR	Proton NMR
HRMS	High resolution mass spectrometry
HSQC	Heteronuclear single quantum coherence
IC <sub>50</sub>	50% inhibitory concentration
IL-4	Interleukin-4
IPT	Intermittent preventative treatment
IR	Infrared spectroscopy
IRS	Indoor residual spraying
ITN	Insecticide treated nets
NADPH	Nicotinamide adenine dinucleotide phosphate
NMR	Nuclear magnetic resonance

npRBCs	Non-parasitized red blood cells
PABA	Para-aminobenzoic acid
<i>Pfcr1</i>	<i>Plasmodium falciparum</i> chloroquine resistance transporter
<i>pfmdr1</i> gene	<i>Plasmodium falciparum</i> multi-drug resistant gene
Pgh1 efflux pump	P-glycoprotein efflux pump
pRBCs	Parasitized red blood cells
RBM	Roll Back Malaria
RDTs	Rapid diagnostic tests
ROS	Reactive oxygen species
SCD	Sickle cell disease
SCT	Sickle cell trait
SERCA	Sarcoplasmic/endoplasmic reticulum calcium ATPase
SP	Sulfadoxine/pyrimethamine
TGA	Thermogravimetric analysis
THF	Tetrahydrofolate
WHO	World Health Organization